688180 君实生物
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-13.912-27.454-27.404-10.469-37.900
总资产报酬率 ROA (%)-8.349-19.107-20.243-7.576-26.893
投入资产回报率 ROIC (%)-9.985-22.727-24.558-9.379-31.453

边际利润分析
销售毛利率 (%)74.40763.99665.30469.07976.642
营业利润率 (%)-76.237-163.551-183.414-13.871-103.836
息税前利润/营业总收入 (%)-76.865-170.296-189.759-14.004-103.533
净利润/营业总收入 (%)-77.779-168.759-177.784-18.151-104.622

收益指标分析
经营活动净收益/利润总额(%)100.53992.68098.964118.222102.386
价值变动净收益/利润总额(%)4.7943.0181.913-11.050-2.417
营业外收支净额/利润总额(%)1.5771.3750.4216.1720.977

偿债能力分析
流动比率 (X)1.9962.2854.0862.9203.191
速动比率 (X)1.7492.0643.7462.6782.958
资产负债率 (%)42.16135.46122.15324.63627.129
带息债务/全部投入资本 (%)29.49118.73910.6975.31711.260
股东权益/带息债务 (%)225.389411.315819.6341,731.442767.704
股东权益/负债合计 (%)134.839177.791340.888292.256268.612
利息保障倍数 (X)-129.60438.14234.070-17.970-77.939

营运能力分析
应收账款周转天数 (天)100.88086.422189.63784.23285.044
存货周转天数 (天)458.727378.341386.772119.759253.231